Source: Eur Respir J 2014; 44: 273-276
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Ryerson Christopher J., Corte Tamera J., Collard Harold R., Richeldi Luca. A global registry for idiopathic pulmonary fibrosis: the time is now. Eur Respir J 2014; 44: 273-276

Member's Comments

No comment yet.

Related content which might interest you: Does early diagnosis of idiopathic pulmonary fibrosis matter? Real- world´s data from the EMPIRE registry Source: International Congress 2016 – IPF: from pathogenesis to treatment I Year: 2016 A global perspective on acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF): results from an international survey Source: International Congress 2018 – Clinical news in idiopathic interstitial pneumonias Year: 2018 Clinical outcomes of patients with idiopathic pulmonary fibrosis in clinical practice: Follow-up results of the INSIGHTS-IPF registry Source: International Congress 2015 – IPF: clinical aspects II Year: 2015 Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry Source: Eur Respir J 2015; 46: 186-196 Year: 2015 Onset of symptoms in idiopathic pulmonary fibrosis: A case-control study Source: International Congress 2016 – IPF: from pathogenesis to treatment I Year: 2016 Validation of GAP score in Danish patients diagnosed with idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease II Year: 2013 Idiopathic pulmonary fibrosis: time for greater expectations? Source: Eur Respir J, 52 (2) 1801312; 10.1183/13993003.01312-2018 Year: 2018 Beyond idiopathic pulmonary fibrosis: the world of progressive-fibrosing interstitial lung disease Source: Eur Respir Rev, 27 (150) 180110; 10.1183/16000617.0110-2018 Year: 2018 Disease progression in early idiopathic pulmonary fibrosis: Insights from the Australian IPF registry Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Efficacy of pirfenidone in idiopathic pulmonary fibrosis: A single center experience Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Risk prediction and end-points in idiopathic pulmonary fibrosis: one step at a time Source: Eur Respir J 2014; 43: 1237-1239 Year: 2014 Pirfenidone treatment in idiopathic pulmonary fibrosis: An Italian case series Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 The epidemiologic features and the patterns of medical resource use in idiopathic pulmonary fibrosis (IPF) in Korea Source: International Congress 2015 – IPF: clinical aspects Year: 2015 The lived experience of idiopatic pulmonary fibrosis: A qualitative study Source: International Congress 2016 – Respiratory nursing research: opening new perspectives on patient experiences Year: 2016 Management of idiopathic pulmonary fibrosis: selected case reports Source: Eur Respir Rev 2014; 23:239-248 Year: 2014 Does delay in review of newly-diagnosed idiopathic pulmonary fibrosis (IPF) worsen outcomes? Source: International Congress 2018 – News on the diagnosis of idiopathic interstitial pneumonia Year: 2018 Inspiration plus: baseline characteristics of the canadian registry for IPF patients on pirfenidone Source: International Congress 2016 – Orphan diseases II Year: 2016 Clinical characteristics of patients with Idiopathic pulmonary fibrosis in a tertiary care center of a developing country Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016 Healthy survivor bias in patients with idiopathic pulmonary fibrosis in clinical registries. Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021 Severe idiopathic pulmonary fibrosis: what can be done? Source: Eur Respir Rev, 26 (145) 170047; 10.1183/16000617.0047-2017 Year: 2017